Bowel diseases Etrolizumab IND Filgotinib IND Mirikizumab Ozanimod IND Risankizumab IND Tenapanor Upadacitinib IND Vedolizumab IND Cardiovascular diseases Avacopan Other chronic immune diseases Adrenaline Arachis hypogaea (pinda) allergenen (capsule) Arachis hypogaea (pinda) allergenen (pleister) Baricitinib Systemic lupus erythematosus IND Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant. IND Belatacept IND Belimumab IND Berotralstat Budesonide modified released capsule IND Canakinumab IND Icatibant G Imlifidase MDR-101 Mavorixafor RP-L201 Sutimlimab Teprotumumab Voclosporin Rheumatism Anifrolumab Cyclobenzaprine hydrochloride Risankizumab IND Sarilumab IND Secukinumab IND Tofacitinib Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs. Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. IND Extension of indication for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. IND Skin diseases Abrocitinib Beremagene geperpavec Berkenschorsextract Bimekizumab Crisaborole Deucravacitinib Difelikefalin Lebrikizumab Ligelizumab Regenerative Skin Tissue Risankizumab IND Ruxolitinib Secukinumab IND Spesolimab Tapinarof Adult Plaque Psoriasis Atopische dermatitis Tirbanibulin Tralokinumab Upadacitinib IND Unknown Olopatadine / mometasone